Robert R. Henry

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

John B. Buse, Robert R. Henry, Jenny Han et al. · Diabetes Care · 2004 · 1.3K citations · Full text

Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects

Timothy E. Graham, Qin Yang, Matthias Blüher et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Alan J. Garber, Robert R. Henry, Robert E. Ratner et al. · The Lancet · 2008 · 1K citations

Diabetes Management, Diabetes, Pharmacology +7

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal et al. · Gastroenterology · 2013 · 906 citations

Metabolic Syndrome, Hepatology, Nonalcoholic Fatty Liver Disease +9

Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY

Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay et al. · Endocrine Practice · 2016 · 874 citations

Metabolic Syndrome, Diabetes Management, Comprehensive Type 2 +5